


Structure-based drug design --> dual receptor/signal pathway selectivity --> biological insights & safer therapeutics



University of Copenhagen, SARomics Biostructures and Enamine join forces to develop the next generation of safer anti-depressants.

Depression is one of the most common mental illnesses. The WHO lists depression as one of the most debilitating conditions in the world, with severe depression rated in the same disability category as terminal stage cancer. Unfortunately, current antidepressant treatments fail to alleviate the suffering of up to 30% of the affected patients.

Backed by a EU grant of 1.3 mill Euro, the newly establish Marie Curie industrial doctorate training network **SAFER** will strive to identify functionally **Selective Agonists For** the 5-HT_{2A} **Serotonin Receptor** and thus provide novel tools dissecting serotonin signaling within the brain. This will guide the discovery novel chemical entities, which eventually will provide more effective and safe drugs for the treatment of depression.

SAFER is now recruiting 5 PhD students to work within pharmacology, medicinal chemistry, crystallography, computational drug design and scientific database development. They will work tightly together to achieve the common scientific objectives of identifying mechanisms, tools and drug-like compounds for selective signaling through the serotonin 5-HT_{2A} receptor drug target. All PhD students will get initial research training from four leading research groups at the University of Copenhagen, then move to conduct 1.5-2 years of innovative research and training in industry at Enamine, Kiev, Ukraine or SARomics Biostructures, Lund, Sweden.

For more information about the project and the available positions, see <http://www.safer-itn.eu/>

The University of Copenhagen is the largest research and education institution in Denmark with more than 40.000 enrolled students. Internationally, the University is highly competitive and the most recent Shanghai rankings placed the University as No. 30 worldwide and No. 6 in Europe.

Enamine is a chemical and bio-screening company committed to providing life science industries with a wide spectrum of state-of-the-art chemistry solutions to support their efforts in the design of new drugs and other bioactive products. Enamine provides the world's largest catalogue of in-stock chemical compounds (>2 million), offers rapid on-demand synthesis and has recently expanded the services to high-throughput biological/pharmacological screening.

SARomics Biostructures is a research-based company within the broad field of structural biology, with a focus in early stage drug discovery using protein crystallography and structure-based drug design as central tools. The company has built a global reputation for its structure-based drug design skills and technology platform and is currently supporting clients in Asia, Europe and North America to pursue their drug discovery objectives. In parallel the expertise is applied to a number of innovative early stage drug discovery projects aiming to discover leads for new medicines.